

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective Oct. 1, 2021 – Part 1

DRUG LIST CHANGES

Based on the availability of new prescription medications and Prime's National Pharmacy and Therapeutics Committee's review of changes in the pharmaceuticals market, some revisions (drugs still covered but moved to a higher out-of-pocket payment level) and/or exclusions (drugs no longer covered) will be made to the Blue Cross and Blue Shield of New Mexico (BCBSNM) drug lists. Your patient(s) may ask you about therapeutic or lower cost alternatives if their medication is affected by one of these changes. Changes effective Oct. 1, 2021 are outlined below.

The Quarterly Pharmacy Changes Part 2 article with more recent coverage additions will also be published closer to the October 1 effective date.

Drug List Updates (Revisions/Exclusions) - As of Oct. 1, 2021

Non-Preferred Brand ¹	Drug Class/ Condition Used For	Preferred Generic Alternative(s) ²	Preferred Brand Alternative(s) ^{1, 2}
Basic, Multi-Tie	r Basic, Enhanced and	d Multi-Tier Enhanced Dru	g List Revisions
ALINIA (nitazoxanide tab 500 mg)	Parasitic Infections	Generic equivalent availa to their doctor or pharmac medication(s) available fo	rist about other or their condition.
GLUCAGON EMERGENCY KIT (glucagon (rdna) for inj kit 1 mg)	Hypoglycemia	Generic equivalent availa to their doctor or pharmac medication(s) available fo	ist about other
ZYTIGA (abiraterone acetate tab 500 mg)	Cancer	Generic equivalent availa to their doctor or pharmac medication(s) available fo	ist about other
	Basic and Multi-Tier	Basic Drug List Revisions	i
AZOPT (brinzolamide ophth susp 1%)	Ocular Hypertension, Glaucoma	Generic equivalent availa to their doctor or pharmac medication(s) available fo	ist about other
ALPHAGAN P (brimo nidine ophth soln 0.1%)	Ocular Hypertension, Glaucoma	brimonidine tartrate 0.15%, brimonidine tartrate 0.2%, apraclonidine 0.5%, lopidine 1%, Simbrinza	
CARAC (fluorouracil cream 0.5%)	Actinic Keratosis	diclofenac gel (3%), fluorouracil cream (5%), fluorouracil solution (2%, 5%)	
CELLCEPT (mycophenolate mofetil cap 250 mg)	Transplant Rejection Prophylaxis	Generic equivalent availa to their doctor or pharmac medication(s) available fo	rist about other or their condition.
CELLCEPT (mycophenolate mofetil tab 500 mg)	Transplant Rejection Prophylaxis	Generic equivalent availa to their doctor or pharmac medication(s) available fo	ist about other
CELONTIN (methsuximide cap 300 mg)	Seizures	ethosuximide capsules, ethosuximide solution	

DEXAMETHASONE	Inflammatory	dexamethasone tablets,	
(dexamethasone soln	Conditions	dexamethasone elixir	
0.5 mg/5 ml)	001141110110	0.5 mg/5 ml	
DROXIA (hydroxyurea	Sickle Cell Anemia	hydroxyurea capsule	
cap 200 mg, 300 mg,	Clottle Con , thomas	500 mg	
400 mg)		ooo mg	
EPOGEN (epoetin alfa	Anemia		Procrit, Retacrit
inj 2000 unit/ml, 3000	7 (Horrita		r room, rectaone
unit/ml, 4000 unit/ml,			
10000 unit/ml, 20000			
unit/ml)			
FLUOROPLEX	Actinic Keratosis	diclofenac gel (3%),	
(fluorouracil cream 1%)	Actimic Neratosis	fluorouracil cream (5%),	
(Hadroaradirerdam 170)		fluorouracil solution (2%,	
		5%)	
INNOPRAN XL	Hypertension	propranolol hcl cap ER	
(propranolol hcl	riyperterision	24hr	
sustained-release beads		24111	
cap er 24hr 80 mg, 24hr			
120 mg)			
LOTEMAX (lotepred nol	Ocular	Generic equivalent availa	hle Memhers should talk
etabonate ophth gel	Hypertension,	to their doctor or pharmac	
0.5%)	Glaucoma	medication(s) available fo	
PREDNISONE	Inflammatory	prednisone 5 mg/5 ml	tricii coriaitiori.
INTENSOL (prednisone	Conditions	solution, prednisolone	
conc 5 mg/ml)	Conditions	sodium phosphate 10	
Cone o mg/m)		mg/5 ml, 15 mg/5 ml, 20	
		mg/5 ml	
PROGRAF (tacrolimus	Transplant Rejection	Generic equivalent availa	ble. Members should talk
cap 0.5 mg, 1 mg, 5 mg)	Prophylaxis	to their doctor or pharmac	
		medication(s) available fo	
PROGRAF (tacrolimus	Transplant Rejection	tacrolimus capsules	
packet for susp 0.2 mg,	Prophylaxis		
1 mg)			
SIVEXTRO (tedizolid	Infections	Members should talk to th	neir doctor or pharmacist
phosphate for iv soln		about other medication(s)	
200 mg)		condition.	
SIVEXTRO (tedizolid	Infections	Members should talk to th	neir doctor or pharmacist
phosphate tab 200 mg)		about other medication(s)	
		condition.	
TREXALL (methotrexate	Rheumatoid	methotrexate 2.5 mg	
sodium tab 5 mg, 7.5	Arthritis,	tablet	
mg, 10 mg, 15 mg (base	Polyarticular		
equiv))	Juvenile Idiopathic		
	Arthritis, Psoriasis,		
	Cancer		
ZORTRESS (everolimus	Transplant Rejection	Generic equivalent availa	ble. Members should talk
tab 0.25 mg, 0.5 mg,	Prophylaxis	to their doctor or pharmac	
0.75 mg, 1 mg)		medication(s) available fo	
ZYCLARA (imiquimod	Actinic Keratosis,	Generic equivalent availa	ble. Members should talk
cream 3.75%)	Warts	to their doctor or pharmac	
		medication(s) available fo	
ZYCLARA PUMP	Actinic Keratosis	imiquimod cream 3.75%	
(imiquimod cream 2.5%)		-	

ZYCLARA PUMP (imiquimod cream 3.75%)	Actinic Keratosis, Warts		Generic equivalent available. Members should talk to their doctor or pharmacist about other medication(s) available for their condition.		
Enhanced and Multi-Tier Enhanced Drug List Revisions					
CEREZYME (imiglucerase for inj 400 unit)		Disease	Members should talk to their doctor or pharmacist about other medication(s) available for their condition.		
NAGLAZYME (galsulfase soln for iv infusion 1 mg/ml)	Mucopo sis VI (M	lysaccharido IPS VI)		s should talk to their do er medication(s) avail	
V					
Drug ¹		Dru Class/Co Used	ndition For	Generic Alternatives ^{1,2}	Brand Alternatives ^{1,2}
			formance :	Select Drug List Revi	
CEFACLOR (cefaclor cap 500 mg)	250 mg,	Infections		Members should tall pharmacist about ot available for their co	her medication(s)
CEFADROXIL (cefadroxil gm)	tab 1	Infections		Members should talk to their doctor or pharmacist about other medication(s) available for their condition.	
CYCLOSERINE (cycloserine cap 250 mg)		Infections	Infections Members should talk to their doc pharmacist about other medicatio available for their condition.		her medication(s) Indition.
SPS (sodium polystyrene	/60 ml)	Hyperkalen	nia		Lokelma, Veltassa
sulfonate oral susp 15 gm/60 ml) VCF VAGINAL CONTRACEPTIVE GEL (nonoxynol-9 gel 4%)		Contracepti	ive		Encare, Options Glynol Vaginal, VCF Vaginal Contraceptive foam
		Balanced Dru	ug List Rev		
ACETAMINOPHEN/CAFFEINE/DI HYDROCODEINE (acetaminophen-caffeine- dihydrocodeine tab 325-30-16 mg)		Pain		acetaminophen W/codeine tablet	
FLUOXETINE HYDROCHLORIDE (fluoxetine hcl (pmdd) tab 10 mg, 20 mg)		Premenstru dysphoric d		fluoxetine capsule	
MORPHINE SULFATE ER (morphine sulfate cap er 24hr 40 mg)		Pain		morphine sulfate cap er 24hr 20 mg	Xtampza ER
naproxen tab ec 375 mg,	500 mg	Pain, Inflam	nmation	ibuprofen tablet, naproxen tablet (non-enteric coated)	
VTOL LQ (butalbital- acetaminophen-caffeine s 325-40 mg/15 ml)	oln 50-	Pain		butalbital- acetaminophen- caffeine 50-325-40 mg tablet	

Balanced Performa	nce and Performance S	Soloct Drug List Excl	usions
FEMRING (estradiol acetate	Menopause	estradiol patches,	Estring, Premarin
vaginal ring 0.05 mg/24hr, 0.1 mg/24hr)	Symptoms	estradiol tablets	
GLUCAGON EMERGENCY KIT	Hypoglycemia		available. Members
(glucagon (rdna) for inj kit 1 mg)		about other medical their condition.	. ,
LOTEMAX (lotepred nol etabonate ophth gel 0.5%)	Ophthalmic Conditions		available. Members doctor or pharmacist tion(s) available for
SAPHRIS (asenapine maleate sl tab 2.5 mg, 5 mg, 10 mg (base equiv))	Bipolar Disorder, Schizophrenia	Generic equivalent should talk to their cabout other medical their condition.	doctor or pharmacist
ZYTIGA (abiraterone acetate tab 500 mg)	Cancer	Generic equivalent should talk to their cabout other medical their condition.	doctor or pharmacist
	nd Performance Select		ns .
ACETAMINOPHEN/CAFFEINE/DI HYDROCODEINE (acetaminophen-caffeine- dihydrocodeine cap 320.5-30-16 mg)	Pain	acetaminophen w/codeine tablet	
choline fenofibrate cap dr 45 mg (fenofibric acid equiv)	Hypercholesterolemia	fenofibrate 48 mg tablet	
fenofibrate micronized cap 43 mg	Hypercholesterolemia	fenofibrate 48 mg tablet	
methamphetamine hcl tab 5 mg	Attention-Deficit Hyperactivity Disorder (ADHD)	methylphenidate tablet	
naproxen tab ec 375 mg, 500 mg	Pain, Inflammation	ibuprofen tablet, naproxen tablet (non-enteric coated)	
trazodone hcl tab 300 mg	Depression	trazodone 150 mg tablet	
TREZIX (acetaminophen-caffeine- dihydrocodeine cap 320.5-30-16 mg)	Pain	acetaminophen w/codeine tablet	
	I B. 6	11.45	
	Performance Select D		and table Advists
ZYCLARA (imiquimod cream 3.75%)	Actinic Keratosis	should talk to their of about other medical their condition.	,
ZYCLARA PUMP (imiquimod cream 3.75%)	Actinic Keratosis		available. Members doctor or pharmacist tion(s) available for

Balanced Drug List Exclusions			
ACZONE (dapsone gel 7.5%)	Acne, Skin infections	Generic equivalent available. Members should talk to their doctor or pharmacist about other medication(s) available for their condition.	
HYSINGLA ER (hydrocodone bitartrate tab er 24hr deter 20 mg, 24hr deter 30 mg, 24hr deter 40 mg, 24hr deter 60 mg, 24hr deter 80 mg, 24hr deter 100 mg, 24hr deter 120 mg)	Pain	Generic equivalent available. Members should talk to their doctor or pharmacist about other medication(s) available for their condition.	
NAFTIFINE HYDROCHLORIDE (naftifine hcl cream 2%)	Fungal Infections (Topical)	Generic equivalent available. Members should talk to their doctor or pharmacist about other medication(s) available for their condition.	
NORTHERA (droxidopa cap 100 mg, 200 mg, 300 mg)	Neurogenic Orthostatic Hypotension	Generic equivalent available. Members should talk to their doctor or pharmacist about other medication(s) available for their condition.	
VELTIN (clindamycin phosphate-tretinoin gel 1.2-0.025%)	Acne	Generic equivalent available. Members should talk to their doctor or pharmacist about other medication(s) available for their condition.	

¹Third-party brand names are the property of their respective owner.

DISPENSING LIMIT CHANGES

The BCBSNM prescription drug benefit program includes coverage limits on certain medications and drug categories. Dispensing limits are based on U.S. Food and Drug Administration (FDA) approved dosage regimens and product labeling. **Changes by drug list are listed on the charts below.**

BCBSNM letters all members with a claim for a drug included in the Dispensing Limit Program, regardless of the prescribed dosage. This means members may receive a letter even though their prescribed dosage doesn't meet or exceed the dispensing limit.

Effective June 1, 2021:

Drug Class and Medication(s) ¹	Dispensing Limit(s)
Basic, Enhanced, Balanced, Performance and Performance Select Drug Lists	
Imcivree	
setmelanotide solution (IMCIVREE)*	10 mL per 30 days

¹Third-party brand names are the property of their respective owner.

Effective July 1, 2021:

Drug Class and Medication(s) ¹	Dispensing Limit(s)	
Balanced, Performance and Performance Select Drug Lists		
Lupus (formerly Benlysta)		
voclosporin capsule 7.9 mg (LUPKYNIS)*	180 tablets per 30 days	
SA Oncology		
Relugolix tablet 120 mg (ORGOVYX)*	30 tablets per 30 days	

²This list is not all inclusive. Other medicines may be available in this drug class.

^{*} Not all members may have been notified due to limited utilization.

Zokinvy	
lonafarnib capsule 50 mg (ZOKINVY)*	120 capsules per 30 days
lonafarnib capsule 75 mg (ZOKINVY)*	120 capsules per 30 days

¹Third-party brand names are the property of their respective owner.

Effective Oct. 1, 2021:

Drug Class and Medication(s) ¹	Dispensing Limit(s)		
Basic, Enhanced, Balanced, Performance and Performance Select Drug Lists			
Alternative Dosage Form	Alternative Dosage Form		
colesevelam hcl packet for suspension 3.75 gm (WELCHOL)	30 packets per 30 days		
diphenoxylate w/ atropine liquid 2.5-0.025 mg/5 mL (LOMOTIL)	1200 mL per 30 days		
SA Oncology			
ponatinib hcl tab 15 mg (ICLUSIG)	30 tablets per 30 days		
Therapeutic Alternatives			
mefenamic acid capsule (PONSTEL) 250 mg	120 capsules per 30 days		
oxycodone w/ acetaminophen solution 10-300 mg/5 mL (PROLATE)	900 mL per 30 days		

¹Third-party brand names are the property of their respective owner.

Drug Class and Medication(s) ¹	Dispensing Limit(s)	
Basic and Enhanced Drug Lists		
Eysuvis		
loteprednol etabonate ophth susp 0.25% (Eysuvis)	2 bottles per 90 days	
Lupus (formerly Benlysta)		
voclosporin capsule 7.9 mg (LUPKYNIS)	180 tablets per 30 days	
SA Oncology	· · · · · · · · · · · · · · · · · · ·	
Relugolix tablet 120 mg (ORGOVYX)	30 tablets per 30 days	
Zokinvy	· · · · · · · · · · · · · · · · · · ·	
Ionafarnib capsule 50 mg (ZOKINVY)	120 capsules per 30 days	
Ionafarnib capsule 75 mg (ZOKINVY)	120 capsules per 30 days	

¹Third-party brand names are the property of their respective owner.

UTILIZATION MANAGEMENT PROGRAM CHANGES

- Effective **May 1, 2021**, the Diabetes (GLP-1 Receptor Agonists) Step Therapy (ST) program was updated to include generic drugs when available. This program applies to the Basic, Enhanced, Balanced, Performance and Performance Select Drug Lists.
- Effective July 1, 2021, the target drug relugolix tablet 120 mg (ORGOVYX) was added to the Self-administered (SA) Oncology Specialty Prior Authorization (PA) program. This change applies to the Balanced, Performance and Performance Select Drug Lists.
 - o Effective Oct. 1, 2021, this change will apply to the Basic and Enhanced Drug Lists.
- Effective Oct. 1, 2021, the following changes will be applied:
 - Generic targets fenofibrate micronized capsule 130 mg (ANTARA), fenofibrate tablet 40 mg (FENOGLIDE) and fenofibrate tablet 120 mg (FENOGLIDE) will be added to the

^{*} Not all members may have been notified due to limited utilization.

- Fibrates ST program. This change applies to the Basic, Enhanced, Balanced, Performance and Performance Select Drug Lists.
- Targets butalbital-acetaminophen-caffeine solution 50-325-40 mg/15 mL (VANATOL LQ) and spironolactone suspension 25 mg/5 mL (CAROSPIR) will be removed from the Therapeutic Alternatives PA program and added to the Alternative Dosage Form PA program. This change applies to the Basic, Enhanced, Balanced, Performance and Performance Select Drug Lists.

Members were notified about the PA standard program changes listed in the tables below.

Drug categories added to current pharmacy PA standard programs, effective Oct. 1, 2021:

Drug Category	Targeted Medication(s) ¹
Basic a	nd Enhanced Drug Lists
Eysuvis	loteprednol etabonate ophth susp 0.25% (Eysuvis)
Zokinvy	lonafarnib capsule 50 mg (ZOKINVY), lonafarnib capsule 75 mg (ZOKINVY)

¹Third-party brand names are the property of their respective owner.

Targeted drugs added to current pharmacy PA standard programs, effective Oct. 1, 2021:

Drug Category	Targeted Medication(s) ¹	
Basic, Enhanced, Balanced, Performance and Performance Select Drug Lists		
Alternative Dosage Form	colesevelam hcl packet for suspension 3.75 gm (WELCHOL), diphenoxylate w/ atropine liquid 2.5-0.025 mg/5 mL (LOMOTIL)	
Therapeutic Alternatives	mefenamic acid capsule (PONSTEL) 250 mg, oxycodone w/ acetaminophen solution 10-300 mg/5 mL (PROLATE), ursodiol capsule 200 mg (RELTONE), ursodiol capsule 400 mg (RELTONE)	
Basic and Enhanced Drug Lists		
Lupus (formerly Benlysta)	voclosporin capsule (LUPKYNIS)	

¹Third-party brand names are the property of their respective owner.

Per our usual process of member notification prior to implementation, targeted mailings were sent to members affected by drug list revisions and/or exclusions, dispensing limit and prior authorization program changes. For the most up-to-date drug list and list of drug dispensing limits, visit the Pharmacy Program section of our Provider website.

If your patients have any questions about their pharmacy benefits, please advise them to contact the number on their member ID card. Members may also visit *bcbsnm.com* and log in to Blue Access for MembersSM (BAMSM) or MyPrime.com for a variety of online resources.

Reminder: Split Fill Program Available to Select Members

BCBSNM offers its members and groups a Split Fill program to reduce waste and help avoid costs of select specialty medications that may go unused. Members new to therapy (or have not had claims history within the past 120 days for the drug) are provided partial, or "split," prescription fills for up to three months.

The Split Fill Program applies to a specific list of drugs known to have early discontinuation or dose modification. You can view the current list of drugs and find more information on the Split Fill Program on our Provider website.

Please call the number on the member's ID card to verify coverage, or for further assistance or clarification on your patient's benefits.

Change in Benefit Coverage for Select High Cost Products

Several high cost products with available lower cost alternatives will be excluded on the pharmacy benefit for select drug lists. This change impacts BCBSNM members who have prescription drug benefits administered by Prime Therapeutics. This change is part of an ongoing effort to make sure our members and employer groups have access to safe, cost-effective medications.

Based on claims data, members were notified about the following changes to be effective Oct. 1, 2021. Please talk to your patient about other products that may be available.

Please call the number on the member's ID card to verify coverage, or for further assistance or clarification on your patient's benefits.

Product(s) No Longer Covered ^{1*}	Condition Used For	Covered Alternative(s) ^{1,2}
ORPHENADRINE W/ ASPIRIN & CAFFEINE TAB 50-770-60 MG	MUSCLE PAIN	CYCLOBENZAPRINE 5 MG or 10 MG, ORPHENADRINE ER 100 MG

Other high cost products that either are new to market or have therapeutic equivalents available have also been excluded. Please note: Members were not notified of these changes because there is no utilization or the pharmacist can easily fill a member's prescription with the equivalent without needing a new prescription from the doctor. The following drugs are excluded on select drug lists:

Product(s) No Longer Covered ^{1*}	Condition Used For	Covered Alternative(s) ^{1,2}
CLEMASTINE FUMARATE SYRUP 0.67 MG/5 ML	ALLERGIES	CLEMASTINE TAB, CYPROHEPTADINE SYRP
CLINDAGEL GEL 1%	ACNE	OTHER MANUFACTURERS
ivermectin cream 1%	ROSACEA	SOOLANTRA
Symbicort AG (BUDES/FORMOT AER 80; BUDES/FORMOT AER 16)	LUNG DISEASES	SYMBICORT

¹ All brand names are the property of their respective owners.

This list is not all-inclusive. Other products may be available.
 This chart applies to members on the Basic, Multi-Tier Basic, Enhanced and Multi-Tier Enhanced Drug Lists.

Effective May 21, 2021, the drugs listed below are no longer considered high cost products and may be covered on the member's drug list. If the drug is covered on the drug list, members will pay the applicable cost share, based on their benefit plan. If the drug is not covered on the drug list, members can submit a coverage exception.

- CHLORZOXAZONE TAB 500 MG
- PROAIR DIGIHALER

Please call the number on the member's ID card to verify coverage, or for further assistance or clarification on your patient's benefits.

Bowel Preparation Coverage Updates

Starting Aug. 1, 2021, BCBSNM will cover bowel preparation products at \$0 for members 45 years of age and older with an ACA-compliant plan. This change is based on the United States Preventive Services Task Force's recommendation to lower the age for colorectal cancer screening from 50 years of age to 45 years of age.

Currently, two generic products are covered under the Bowel Preparation ACA \$0 preventive benefit:

- PEG 3350-KCL-SOD BICARB-NACL FOR SOLN 420 GM (NULYTELY)
- PEG 3350-KCL-NA BICARB-NACL-NA SULFATE FOR SOLN 236 GM (GOLYTELY)

Please call the number on the member's ID card to verify coverage, or for further assistance or clarification on your patient's benefits.

Prime Therapeutics LLC is a pharmacy benefit management company. BCBSNM contracts with Prime to provide pharmacy benefit management and related other services. BCBSNM, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime. MyPrime.com is an online resource offered by Prime Therapeutics.

The information mentioned here is for informational purposes only and is not a substitute for the independent medical judgment of a physician. Physicians are to exercise their own medical judgment. Pharmacy benefits and limits are subject to the terms set forth in the member's certificate of coverage which may vary from the limits set forth above. The listing of any particular drug or classification of drugs is not a guarantee of benefits. Members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any medication is between the member and their health care provider.